July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

The study systematically characterized RILD using bronchoalveolar lavage and high-resolution CT in 321 patients, mostly with ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.

人体通过被称为细胞凋亡的自然死亡过程每天更换 600 亿个细胞，而癌细胞通常会修改促进细胞凋亡的基因，使自己获得永生。斯坦福医学院的研究人员利用分子胶，重新激活促进细胞凋亡的基因去杀死癌细胞。被称为 BCL6 的蛋白质在发生突变之后会导致被称为 diffuse large cell B-cell lymphoma 的血癌。研究人员利用分子胶将 BCL6 与名为 CDK9 的蛋白质结合起来，CDK9 ...

Treatment for follicular lymphoma is not one-size-fits-all. Many treatments are available for this form of non-Hodgkin's lymphoma. While it may be overwhelming to face so many choices, a wide ...

NATIONAL CANINE LYMPHOMA AWARENESS DAY | NATIONAL CASH BACK DAY | NATIONAL RETINOL DAY | BITTERSWEET CHOCOLATE WITH ALMONDS ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

Nkarta’s pivot from oncology to autoimmune disease has continued with the biotech halting work on its CD19-directed CAR NK in lymphoma to focus on lupus. Seven patients with heavily pretreated large B ...

Viracta Therapeutics is implementing its second round of layoffs in just three months as the cash-strapped biotech tries to keep funds flowing to its lymphoma program. | Viracta Therapeutics is ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...